Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

1.

Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma.

Tetzlaff MT, Curry JL, Ivan D, Wang WL, Torres-Cabala CA, Bassett RL, Valencia KM, McLemore MS, Ross MI, Prieto VG.

Mod Pathol. 2013 Sep;26(9):1153-60. doi: 10.1038/modpathol.2013.59. Epub 2013 Apr 5.

PMID:
23558574
[PubMed - indexed for MEDLINE]
2.

Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.

Nielsen PS, Riber-Hansen R, Jensen TO, Schmidt H, Steiniche T.

Mod Pathol. 2013 Mar;26(3):404-13. doi: 10.1038/modpathol.2012.188. Epub 2012 Nov 23.

PMID:
23174936
[PubMed - indexed for MEDLINE]
Free Article
3.

Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.

Ladstein RG, Bachmann IM, Straume O, Akslen LA.

BMC Cancer. 2010 Apr 14;10:140. doi: 10.1186/1471-2407-10-140.

PMID:
20398247
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma.

Ladstein RG, Bachmann IM, Straume O, Akslen LA.

J Invest Dermatol. 2012 Apr;132(4):1247-52. doi: 10.1038/jid.2011.464. Epub 2012 Feb 2.

PMID:
22297638
[PubMed - indexed for MEDLINE]
Free Article
5.

D2-40/p63 defined lymph vessel invasion has additional prognostic value in highly proliferating operable node negative breast cancer patients.

Gudlaugsson E, Skaland I, Undersrud E, Janssen EA, Søiland H, Baak JP.

Mod Pathol. 2011 Apr;24(4):502-11. doi: 10.1038/modpathol.2010.199. Epub 2011 Feb 11.

PMID:
21317878
[PubMed - indexed for MEDLINE]
Free Article
6.

Useof anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma.

Casper DJ, Ross KI, Messina JL, Sondak VK, Bodden CN, McCardle TW, Glass LF.

Am J Dermatopathol. 2010 Oct;32(7):650-4. doi: 10.1097/DAD.0b013e3181cf7cc1.

PMID:
20559123
[PubMed - indexed for MEDLINE]
7.

Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.

Nasr MR, El-Zammar O.

Am J Dermatopathol. 2008 Apr;30(2):117-22. doi: 10.1097/DAD.0b013e3181624054.

PMID:
18360113
[PubMed - indexed for MEDLINE]
8.

Immunohistochemical dual staining as an adjunct in assessment of mitotic activity in melanoma.

Ikenberg K, Pfaltz M, Rakozy C, Kempf W.

J Cutan Pathol. 2012 Mar;39(3):324-30. doi: 10.1111/j.1600-0560.2011.01858.x.

PMID:
22335591
[PubMed - indexed for MEDLINE]
9.

Differences in tumor thickness between hematoxylin and eosin and Melan-A immunohistochemically stained primary cutaneous melanomas.

Drabeni M, Lopez-Vilaró L, Barranco C, Trevisan G, Gallardo F, Pujol RM.

Am J Dermatopathol. 2013 Feb;35(1):56-63. doi: 10.1097/DAD.0b013e31825ba933.

PMID:
22688397
[PubMed - indexed for MEDLINE]
10.

Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis.

Hale CS, Qian M, Ma MW, Scanlon P, Berman RS, Shapiro RL, Pavlick AC, Shao Y, Polsky D, Osman I, Darvishian F.

Am J Surg Pathol. 2013 Jun;37(6):882-9. doi: 10.1097/PAS.0b013e31827e50fa.

PMID:
23629443
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

pHH3 immunostaining improves interobserver agreement of mitotic index in thin melanomas.

Schimming TT, Grabellus F, Roner M, Pechlivanis S, Sucker A, Bielefeld N, Moll I, Schadendorf D, Hillen U.

Am J Dermatopathol. 2012 May;34(3):266-9. doi: 10.1097/DAD.0b013e31823135a3.

PMID:
22197861
[PubMed - indexed for MEDLINE]
12.

Mitotic rate in cutaneous melanomas ≤1 mm in thickness: a prospective study.

Litzner BR, Etufugh CN, Stepenaskie S, Hynan LS, Cockerell CJ.

Am J Dermatopathol. 2012 Dec;34(8):827-32. doi: 10.1097/DAD.0b013e3182604d96.

PMID:
22878366
[PubMed - indexed for MEDLINE]
13.

Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.

Burton AL, Gilbert J, Farmer RW, Stromberg AJ, Hagendoorn L, Ross MI, Martin RC 2nd, McMasters KM, Scoggins CR, Callender GG.

Am Surg. 2011 Aug;77(8):1009-13.

PMID:
21944515
[PubMed - indexed for MEDLINE]
14.

Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma.

Storr SJ, Safuan S, Mitra A, Elliott F, Walker C, Vasko MJ, Ho B, Cook M, Mohammed RA, Patel PM, Ellis IO, Newton-Bishop JA, Martin SG.

Mod Pathol. 2012 Apr;25(4):493-504. doi: 10.1038/modpathol.2011.182. Epub 2011 Nov 11.

PMID:
22080065
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age.

Skaland I, Janssen EA, Gudlaugsson E, Klos J, Kjellevold KH, Søiland H, Baak JP.

Mod Pathol. 2007 Dec;20(12):1307-15. Epub 2007 Oct 5.

PMID:
17917671
[PubMed - indexed for MEDLINE]
Free Article
16.

Sentinel lymph node biopsy for melanoma: experience with 234 consecutive procedures.

Wagner JD, Corbett L, Park HM, Davidson D, Coleman JJ, Havlik RJ, Hayes JT 2nd.

Plast Reconstr Surg. 2000 May;105(6):1956-66.

PMID:
10839392
[PubMed - indexed for MEDLINE]
17.

Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.

Vitoux D, Mourah S, Kerob D, Verola O, Basset-Seguin N, Baccard M, Schartz N, Ollivaud L, Archimbaud A, Servant JM, Revol M, Toubert ME, Podgorniak MP, Plassa F, Porcher R, Lebbé C.

Arch Dermatol. 2009 Oct;145(10):1105-13. doi: 10.1001/archdermatol.2009.209.

PMID:
19841396
[PubMed - indexed for MEDLINE]
18.

Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.

Niakosari F, Kahn HJ, McCready D, Ghazarian D, Rotstein LE, Marks A, Kiss A, From L.

Arch Dermatol. 2008 Apr;144(4):462-7. doi: 10.1001/archderm.144.4.462.

PMID:
18427039
[PubMed - indexed for MEDLINE]
19.

Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas.

Colman H, Giannini C, Huang L, Gonzalez J, Hess K, Bruner J, Fuller G, Langford L, Pelloski C, Aaron J, Burger P, Aldape K.

Am J Surg Pathol. 2006 May;30(5):657-64.

PMID:
16699322
[PubMed - indexed for MEDLINE]
20.

Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas.

Kim YJ, Ketter R, Steudel WI, Feiden W.

Am J Clin Pathol. 2007 Jul;128(1):118-25.

PMID:
17580279
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk